Single administration of recombinant FVIII/placebo in healthy male subjects who have been treated with a single dose of anti-factor VIII antibody, TB-402
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
DOUBLE
Enrollment
12
Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402
Cyncron CRU
Copenhagen, Denmark
Changes in coagulation parameters after rFVIII administration
Time frame: To study end
PD of TB-402, safety of TB-402 alone and with rFVIII, PK of FVIII in rFVIII-treated subjects, changes in coagulation parameters after TB-402 administration
Time frame: To study end
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.